<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03055338</url>
  </required_header>
  <id_info>
    <org_study_id>8189-005</org_study_id>
    <nct_id>NCT03055338</nct_id>
  </id_info>
  <brief_title>An Active-Controlled Early Phase Study of MK-8189 in Adults With Schizophrenia (MK-8189-005)</brief_title>
  <official_title>A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the Efficacy and Safety of MK-8189 Using Risperidone as an Active Control in Subjects Experiencing an Acute Episode of Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a randomized, placebo-controlled, parallel-group, multi-site, double-blind trial
      of MK-8189 compared with placebo, using Risperidone as an active control. The participants
      will be adult subjects experiencing an acute episode of schizophrenia, according to the
      criteria specified in the Diagnostic and Statistical Manual of Mental Disorders, 5th ed.
      (DSM-5). This study will be up to 7 weeks in duration, with up to 7 site visits for each
      participant. The study will consist of a Screening/tapering period (up to one week long), a
      4-week treatment period, and a 14-day follow-up period. The primary objective will be to
      assess symptoms of schizophrenia at 4 weeks, and to assess safety and tolerability during
      treatment and post-treatment follow-up. The secondary objective will be to assess the
      severity of schizophrenia at 4 weeks. The primary hypothesis is that MK-8189 is superior to
      placebo in reducing the overall symptoms of schizophrenia as assessed by the mean change from
      baseline in the Positive and Negative Syndrome Scale (PANSS) total score after 4 weeks of
      treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 8, 2017</start_date>
  <completion_date type="Actual">January 9, 2018</completion_date>
  <primary_completion_date type="Actual">January 9, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomly assigned to one of three groups in parallel for the duration of the study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>A double-blind/masking technique will be used. MK-8189 and risperidone will be packaged identically relative to their respective matching placebo so that blinding/masking is maintained.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the PANSS total score at Week 4</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <description>The Structured Clinical Interview for the PANSS, a 30-item clinician-rated instrument for assessing the symptoms of schizophrenia, will be used.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who experienced at least one adverse event (AE)</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <description>From the time of treatment allocation/randomization through 14 days following cessation of treatment at Week 4, all AEs will be reported by the investigator.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who discontinued study drug due to an AE</measure>
    <time_frame>4 weeks</time_frame>
    <description>Any AE which led to discontinuation will be followed in accordance with the study's safety requirements. In addition, participants who discontinue from treatment will have 2 follow-up phone call visits and a follow-up clinic visit after their last dose of study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Clinical Global Impression-Severity of Illness (CGI-S) score at Week 4</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <description>The CGI-S, a 7-point clinician-rated scale for assessing the global severity of the illness, will be used.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">225</enrollment>
  <condition>Schizophrenia, Acute Episode</condition>
  <arm_group>
    <arm_group_label>MK-8189</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive double-blind MK-8189 4 mg controlled release (CR) tablet(s) once daily (QD) over 4 weeks. In a 3-step dose escalation regimen over 1 week, participants will receive MK-8189 at the following dose strengths: 4 mg (1 tablet) QD, 8 mg (2 tablets) QD, and 12 mg (3 tablets) QD. Participants will achieve the final dose of 12 mg, as tolerated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Risperidone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive double-blind Risperidone 2 mg capsule(s) QD over 4 weeks. In a 3-step dose escalation regimen over 1 week, participants will receive Risperidone at the following dose strengths: 2 mg (1 capsule) QD, 4 mg (2 capsules) QD, and 6 mg (3 capsules) QD. Participants will achieve the final dose of 6 mg, as tolerated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive double-blind matching placebo for the MK-8189 and Risperidone arms: 1 placebo tablet for MK-8189 4g QD, and 1 placebo capsule for Risperidone 2 mg QD. Participants will receive matching double-blind placebo over 1 week in mock dose escalation consistent with that of the MK-8189 and Risperidone doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-8189</intervention_name>
    <description>Dose strengths: 4 mg (1 tablet); 8 mg (2 tablets); 12 mg (3 tablets)</description>
    <arm_group_label>MK-8189</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone</intervention_name>
    <description>Dose strengths: 2 mg (1 capsule); 4 mg (2 capsules); 6 mg (3 capsules)</description>
    <arm_group_label>Risperidone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Double dummy matching placebo for the MK-8189 tablet and Risperidone capsule treatment arms</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 to 50 years of age at Screening

          -  Male

          -  Female not of reproductive potential (e.g., postmenopausal or has had a hysterectomy),
             or agrees to practice abstinence or use acceptable contraception

          -  Meets the diagnostic criteria for schizophrenia according to the DSM-5 criteria, or
             has a past diagnosis of schizophrenia with the onset of the first episode being &gt;=1
             year prior to study entry, and has illness duration of &lt;=20 years

          -  Is confirmed to be experiencing an acute episode of schizophrenia

          -  Minimum PANSS score &gt;= 80 at Screening

          -  Has a score of &gt;=4 in 3 or more of the following items (delusions, conceptual
             disorganization, hallucinatory behavior, grandiosity, suspiciousness/persecution) in
             the positive subscale of the PANSS at Screening

          -  Has a CGI-S score &gt;= 4 at Screening

          -  Is able to taper off psychotropic medications without significant destabilization or
             increased suicidiality

          -  Has responded positively to an antipsychotic medication other than clozapine in a
             prior psychotic episode

          -  Has an identified responsible external contact person who has regular contact (no less
             than once per week) with the participant

        Exclusion Criteria:

          -  Is currently under involuntary commitment because he/she is considered a danger to
             himself/herself or others

          -  Is unwilling to remain hospitalized for the duration of trial treatment

          -  Is currently participating in or has participated in an interventional clinical
             research study &lt;=6 months prior to Screening, or has participated in more than one
             interventional clinical trial research study within 12 months prior to Screening

          -  Is unwilling to allow audio/video taping of the Mini International Neuropsychiatric
             Interview for Schizophrenia and Psychotic Disorders (MINI) and/or PANSS interview at
             Screening and Baseline

          -  Is currently being treated with and benefiting from medications with a moderate or
             strong inhibiting or inducing effect on CYP3A and/or CYP2C9 and/or sensitive
             substrates of CYP2B6

          -  Has a history of malignancy &lt;= 5 years except for adequately treated basal cell or
             squamous cell skin cancer or in situ cervical cancer

          -  Has a body mass index &lt;18.5 or &gt;40 kg/mË„2

          -  Has a history of treatment-resistant schizophrenia

          -  Has a prolactin laboratory value of &gt;= 5 times the upper limit of normal at Screening

          -  Has a known history or clinical evidence of clinically significant hepatic,
             cardiovascular, or renal disease, or of untreated narrow-angle glaucoma

          -  Has ever been diagnosed with epilepsy or had any seizure disorder beyond one childhood
             febrile seizure

          -  Has known serological evidence of human immunodeficiency virus (HIV) antibody

          -  Has a history of neuroleptic malignant syndrome

          -  Has a current diagnosis other than schizophrenia, or a comorbid diagnosis primarily
             responsible for current symptoms and functional impairment

          -  Has a known history of borderline personality disorder, antisocial personality
             disorder, or bipolar disorder

          -  Has a known history of traumatic brain injury, or Alzheimer's disease or another form
             of dementia

          -  Currently meets DSM-5 criteria for substance abuse or alcohol use disorder

          -  Is at imminent risk of self-harm or harm to others
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Woodland International Research Group, LLC ( Site 0001)</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Woodland Research Northwest, LLC ( Site 0014)</name>
      <address>
        <city>Rogers</city>
        <state>Arkansas</state>
        <zip>72758</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CITRIALS ( Site 0013)</name>
      <address>
        <city>Bellflower</city>
        <state>California</state>
        <zip>90706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Clinical Development ( Site 0049)</name>
      <address>
        <city>Cerritos</city>
        <state>California</state>
        <zip>90703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network, LLC ( Site 0057)</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Behavioral Research Specialists, LLC ( Site 0006)</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synergy East ( Site 0003)</name>
      <address>
        <city>Lemon Grove</city>
        <state>California</state>
        <zip>91945</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NRC Research Institute ( Site 0043)</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CNRI - Los Angeles, LLC ( Site 0026)</name>
      <address>
        <city>Pico Rivera</city>
        <state>California</state>
        <zip>90660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Artemis Institute for Clinical Research ( Site 0027)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schuster Medical Research Institute ( Site 0032)</name>
      <address>
        <city>Sherman Oaks</city>
        <state>California</state>
        <zip>91403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network, LLC ( Site 0046)</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Larkin Community Hospital Behavioral Health Services ( Site 0020)</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Centers of America, LLC ( Site 0038)</name>
      <address>
        <city>Oakland Park</city>
        <state>Florida</state>
        <zip>33334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aspire Health Partners ( Site 0016)</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research - Atlanta ( Site 0008)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Center For Medical Research ( Site 0056)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alexian Center for Psychiatric Research ( Site 0015)</name>
      <address>
        <city>Hoffman Estates</city>
        <state>Illinois</state>
        <zip>60169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lake Charles Clinical Trials, LLC ( Site 0040)</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <zip>70629</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CBH Health, LLC ( Site 0022)</name>
      <address>
        <city>Gaithersburg</city>
        <state>Maryland</state>
        <zip>20877</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Precise Research Centers ( Site 0018)</name>
      <address>
        <city>Flowood</city>
        <state>Mississippi</state>
        <zip>39232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psych Care Consultants Research ( Site 0025)</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis Clinical Trials, LLC ( Site 0012)</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altea Research Institute ( Site 0017)</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research -CliniLabs ( Site 0037)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Clinical Research Unit ( Site 0041)</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InSite Clinical Research ( Site 0033)</name>
      <address>
        <city>DeSoto</city>
        <state>Texas</state>
        <zip>75115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pillar Clinical Research, LLC ( Site 0004)</name>
      <address>
        <city>Richardson</city>
        <state>Texas</state>
        <zip>75080</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2017</study_first_submitted>
  <study_first_submitted_qc>February 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 16, 2017</study_first_posted>
  <last_update_submitted>March 29, 2018</last_update_submitted>
  <last_update_submitted_qc>March 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Schizophrenia, acute episode</keyword>
  <keyword>Schizophrenia Spectrum and Other Psychotic Disorders</keyword>
  <keyword>Mental Disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

